JACKSON CENTER, Pa., Jan. 11, 2018 -- Premier Biomedical, Inc. (OTC:BIEI) announced the signing of an agreement with HealthWarehouse.com, Inc. (OTC:HEWA) to market, sell and distribute Premier’s topical pain relief products. HealthWarehouse.com is the nation’s largest on-line distributor of prescription and over-the-counter drugs and health supplements. This augments Premier’s existing internet sales through their website, www.painreliefmeds.com, and other direct outlets announced in earlier press releases. The agreement covers not only Premier’s existing five pain relief products, but also those planned for the future. The deal also includes the right of HealthWarehouse.com to advertise these products in their catalogs.
Premier Biomedical’s existing topical pain relief products include a 96-hour topical skin patch, oil-based and water-based roll-ons, an oil-based spray and the newly introduced oil-based ointment. All of Premier’s products are made from all-natural, non-GMO, solvent- and pesticide-free ingredients.
Joe Peters, CEO of HealthWarehouse.com, Inc., stated, “People suffering with pain desperately need an alternative to opioid treatment. HealthWarehouse acts as an advocate to help consumers make their health conditions more manageable by increasing the accessibility of prescription and OTC products through lower prices and online access. Premier Biomedical’s complete line of pain relief products provides an affordable, high quality, pain relief alternative to our customer base.”
William A. Hartman, President & CEO of Premier Biomedical, Inc., stated, “We are very excited that we have been able to secure HealthWarehouse as a partner to provide these opioid alternative pain relief products to a much wider customer base. Once people try our products, they will agree that they outperform every other competitive product in relieving pain and suffering, without the dangerous and addictive side-effects associated with opioids.”
Hartman continued, “This represents a significant increase in our business potential, and we look forward to an expansion of sales now, and in the future.”
For more information please contact:
William A. Hartman
President and CEO
Premier Biomedical, Inc.
Pain Relief Meds
(724) 633-7033
[email protected]
www.premierbiomedical.com/
About HealthWarehouse
HealthWarehouse.com, Inc. (OTC:HEWA) is a trusted VIPPS (Verified Internet Pharmacy Practice Sites) accredited online pharmacy based in Florence, Kentucky. The Company is focused on the growing out-of-pocket prescription market, which has grown to over $80 billion. With a mission to provide affordable healthcare to every American by focusing on technology that is revolutionizing prescription delivery, HealthWarehouse.com has become the largest VIPPS accredited online pharmacy in the United States. HealthWarehouse.com is licensed in all 50 states and only sells drugs that are FDA approved and legal for sale in the United States. Visit HealthWarehouse.com online at http://www.HealthWarehouse.com.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTC:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI."For more information please visit our website: http://www.premierbiomedical.com/.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Source: Uptick Newswire


Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Anta Sports Expands Global Footprint With Strategic Puma Stake
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Samsung Electronics Shares Jump on HBM4 Mass Production Report
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Washington Post Publisher Will Lewis Steps Down After Layoffs
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 



